HK1000933A1 - Method of treating androgenic alopecia with 5-alpha reductase inhibitors - Google Patents

Method of treating androgenic alopecia with 5-alpha reductase inhibitors

Info

Publication number
HK1000933A1
HK1000933A1 HK97102425A HK97102425A HK1000933A1 HK 1000933 A1 HK1000933 A1 HK 1000933A1 HK 97102425 A HK97102425 A HK 97102425A HK 97102425 A HK97102425 A HK 97102425A HK 1000933 A1 HK1000933 A1 HK 1000933A1
Authority
HK
Hong Kong
Prior art keywords
reductase inhibitors
alpha reductase
androgenic alopecia
treating androgenic
treating
Prior art date
Application number
HK97102425A
Other languages
English (en)
Inventor
Glenn J Gormley
Keith D Kaufman
Elizabeth Stoner
Joanne Waldstreicher
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22482390&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1000933(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of HK1000933A1 publication Critical patent/HK1000933A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
HK97102425A 1993-10-15 1997-12-15 Method of treating androgenic alopecia with 5-alpha reductase inhibitors HK1000933A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13852093A 1993-10-15 1993-10-15

Publications (1)

Publication Number Publication Date
HK1000933A1 true HK1000933A1 (en) 1998-05-08

Family

ID=22482390

Family Applications (1)

Application Number Title Priority Date Filing Date
HK97102425A HK1000933A1 (en) 1993-10-15 1997-12-15 Method of treating androgenic alopecia with 5-alpha reductase inhibitors

Country Status (8)

Country Link
US (4) US5547957A (xx)
EP (1) EP0776664A2 (xx)
KR (1) KR100375083B1 (xx)
CO (1) CO4290359A1 (xx)
HK (1) HK1000933A1 (xx)
MY (2) MY123960A (xx)
YU (1) YU49026B (xx)
ZA (1) ZA948064B (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547957A (en) * 1993-10-15 1996-08-20 Merck & Co., Inc. Method of treating androgenic alopecia with 5-α reductase inhibitors
TW382595B (en) * 1993-10-15 2000-02-21 Merck & Co Inc Pharmaceutical composition for use in arresting and reversing androgenic alopecia
EP0724592B1 (en) * 1993-10-21 1999-01-07 Merck & Co. Inc. 16-substituted-4-aza-androstane 5-alpha-reductase isozyme 1 inhibitors
US6001844A (en) 1995-09-15 1999-12-14 Merck & Co., Inc. 4-Azasteroids for treatment of hyperandrogenic conditions
AU704933B2 (en) * 1995-10-19 1999-05-06 Merck & Co., Inc. 16-substituted-6-aza-steroid 5-alpha-reductase inhibitors
US5679378A (en) * 1995-12-18 1997-10-21 Olim Industries Of Israel, North America, Ltd. Method and material for hair therapy
US5935968A (en) * 1997-03-17 1999-08-10 Merck & Co., Inc. Methods for treating polycystic ovary syndrome
US6348348B1 (en) * 1998-04-07 2002-02-19 The Carnegie Institution Of Washington Human hairless gene and protein
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
EP1451144B1 (en) 2001-10-31 2010-09-01 Coreana Cosmetics Co., Ltd. Compositions for treating acne comprising phytandiol amine
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
US7790706B2 (en) * 2002-06-14 2010-09-07 The University Of Edinburgh Treatment of inflammation with 5α reduced metabolites
IL156670A0 (en) * 2003-06-26 2004-01-04 Zvi Zolotariov Aloe suppositories
WO2005003149A1 (en) * 2003-07-03 2005-01-13 Cipla Limited Process for the preparation of finasteride form i
US20050136015A1 (en) * 2003-12-17 2005-06-23 McKie Derrick B. Topical use of halosalicylic acid derivatives
RU2006129320A (ru) * 2004-02-12 2008-02-27 Уорнер-Ламберт Компани Ллс (Us) Способ стимулирования роста волос
GB0407329D0 (en) * 2004-03-31 2004-05-05 Danisco Process
US7979110B1 (en) * 2004-09-23 2011-07-12 Orbital Research Inc. Method for accurate placement of electrodes
WO2006058781A2 (en) 2004-12-03 2006-06-08 Proteosys Ag Finasteride, dutasteride and related compounds for preventing/treating neurologically-associated disorders
US20060263452A1 (en) * 2005-05-17 2006-11-23 Alwyn Dowell Topical composition containing essential oils
US20070167899A1 (en) * 2006-01-19 2007-07-19 Strom Randy A Compression apparatus and method for stimulating hair growth
US20090076058A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched finasteride
US20090203628A1 (en) * 2008-02-12 2009-08-13 Jan Marini Composition, Method And Kit For Treating Skin Disorders And Improving Skin Condition
US20090233954A1 (en) * 2008-03-12 2009-09-17 Goren Andy Ofer Methods and systems for prognosis of a patient's response to treatment of androgenetic skin disorders
EP2378872A4 (en) 2008-12-18 2012-05-16 B Eugene Guthery TREATMENT PLAN FOR ACNE VULGARIS
FR2954124B1 (fr) * 2009-12-18 2012-04-06 Fabre Pierre Dermo Cosmetique Utilisation du 2,3-dihydroxypropyl dodecanoate pour le traitement de la seborrhee
JP2013532720A (ja) * 2010-08-05 2013-08-19 レガシー ヘルスケア ホールディング リミテッド 毛髪成長刺激方法
US8604047B2 (en) * 2010-08-10 2013-12-10 Elorac, Inc. Method and composition for treating nodulocystic and conglobate acne vulgaris
CA2856847A1 (en) * 2011-11-25 2013-05-30 Adrianna Janell JACKSON Oil compositions and methods for increasing hair growth and/or preventing hair loss
KR102064488B1 (ko) * 2019-04-18 2020-01-13 주식회사 엠진 홍삼 추출물 등을 이용한 발모 촉진 또는 탈모 억제용 조성물
KR102221365B1 (ko) 2019-05-07 2021-03-02 (주)케어젠 트롤록스-펩타이드 결합체 및 그의 용도

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US4220775A (en) * 1979-03-15 1980-09-02 Merck & Co., Inc. Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
US4396615A (en) * 1981-06-24 1983-08-02 Duke University Method of treating androgen-related disorders
US4885289A (en) * 1983-12-12 1989-12-05 Breuer Miklos M Alteration of character of male beard growth
US5120742A (en) * 1984-02-27 1992-06-09 Merck & Co., Inc. 17 β-acyl-4-aza-5 α-androst-1-ene-3-ones as 5 α-reductase inhibitors
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
US5049562A (en) * 1984-02-27 1991-09-17 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
US4859681A (en) * 1984-02-27 1989-08-22 Merck & Co., Inc. 17 α-Acyl-4-aza-5a-androst-1-en-3-ones as 5 alpha-reductase inhibitors
US5151429A (en) * 1984-02-27 1992-09-29 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α reductase inhibitors
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
US5053403A (en) * 1984-05-11 1991-10-01 Norman Orentreich Methods for treatment of male-pattern baldness
US4684635A (en) * 1984-05-11 1987-08-04 Norman Orentreich Compositions and methods for inhibiting the action of androgens
EP0285382B1 (en) * 1987-04-03 1994-04-13 Merck & Co. Inc. Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones
EP0285383B1 (en) 1987-04-03 1994-03-16 Merck & Co. Inc. Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones
US5228431A (en) * 1990-04-26 1993-07-20 Giarretto Ralph R Drug-free method for treatment of the scalp for therapeutic purposes
US5098908A (en) * 1990-06-20 1992-03-24 Merck & Co., Inc. 17β-hydroxybenzoyl-4-aza-5α-androst-1-en-3-ones as testosterone reductase inhibitors
US5162332A (en) * 1990-06-20 1992-11-10 Merck & Co., Inc. Selected 17 β-polyaroyl-4-aza-5 α-androst-1-en-3-ones as steroidal reductase inhibitors
CA2085605C (en) * 1990-08-10 2003-03-11 Arthur Robert Diani Stimulation of hair growth with potassium channel openers and 5alpha-reductase inhibitors
US5175155A (en) * 1991-10-07 1992-12-29 Sterling Winthrop Inc. Win 49596-finasteride method of use and compositions
EP0649306B1 (en) 1992-05-20 2001-01-10 Merck & Co. Inc. Ester derivatives of 4-aza-steroids
AU4258493A (en) * 1992-05-21 1993-12-13 Endorecherche Inc. Inhibitors of testosterone 5alpha-reductase activity
US5795882A (en) * 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
US5407944A (en) * 1993-02-19 1995-04-18 Goldman; Boris E. Compositions and methods for promoting hair growth
ATE158301T1 (de) * 1993-06-28 1997-10-15 Merck & Co Inc 4-aza-pregnan-5-alpha-reductase isozym 1 inhibitoren
US5438061A (en) 1993-07-16 1995-08-01 Merck & Co., Inc. 7-substituted-δ4-6-azasteroid derivatives as 5α-reductase inhibitors
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW382595B (en) * 1993-10-15 2000-02-21 Merck & Co Inc Pharmaceutical composition for use in arresting and reversing androgenic alopecia
US5547957A (en) * 1993-10-15 1996-08-20 Merck & Co., Inc. Method of treating androgenic alopecia with 5-α reductase inhibitors
EP0724592B1 (en) * 1993-10-21 1999-01-07 Merck & Co. Inc. 16-substituted-4-aza-androstane 5-alpha-reductase isozyme 1 inhibitors
US5708001A (en) * 1993-12-17 1998-01-13 Glaxo Wellcome Inc. Substituted 6-azaandrostenones
US5525608A (en) * 1994-04-20 1996-06-11 Merck & Co., Inc. 17b-aryl-4-aza-steroid derivatives useful as 5-alpha-reductase inhibitors
US5512555A (en) * 1994-07-21 1996-04-30 Merck & Co., Inc. Method of treating sweat-related conditions using finasteride, epristeride and a cholestan-3-one
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
AU704933B2 (en) * 1995-10-19 1999-05-06 Merck & Co., Inc. 16-substituted-6-aza-steroid 5-alpha-reductase inhibitors
US5763361A (en) * 1995-10-23 1998-06-09 Merck & Co., Inc. 17-alkyl-7-substituted-4-aza steroid derivatives as 5-α-reductase inhibitors
US5777134A (en) * 1995-10-26 1998-07-07 Merck & Co., Inc. 4-oxa and 4-thia steriods
US5780437A (en) * 1995-12-14 1998-07-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US5756507A (en) * 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US5849764A (en) * 1995-12-14 1998-12-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone

Also Published As

Publication number Publication date
MY138240A (en) 2009-05-29
EP0776664A3 (xx) 1997-06-11
US20020042425A1 (en) 2002-04-11
ZA948064B (en) 1995-06-06
US5547957A (en) 1996-08-20
CO4290359A1 (es) 1996-04-17
YU58394A (en) 1999-11-22
KR960704555A (ko) 1996-10-09
US6355649B1 (en) 2002-03-12
US6174892B1 (en) 2001-01-16
MY123960A (en) 2006-06-30
EP0776664A2 (en) 1997-06-04
YU49026B (sh) 2003-07-07
KR100375083B1 (ko) 2003-06-09

Similar Documents

Publication Publication Date Title
HK1000933A1 (en) Method of treating androgenic alopecia with 5-alpha reductase inhibitors
US5925376C1 (en) Method for treating psoriasis using selected phosphorylase kinase inhibitor and additional compounds
PL324970A1 (en) Method of and composition for treating asthma
EP0771203A4 (en) PROCESS FOR TREATING PATHOLOGIES ASSOCIATED WITH BREATHING
AU5403394A (en) Method and apparatus for concurrency of bus operations
AU6239398A (en) Workpiece treating apparatus and method of treating same
EP0866734A4 (en) METHOD AND COMPOSITION FOR TREATING METAL SURFACES
ZA947354B (en) Composition and process for treating metal
ZA963185B (en) Method and compositions for treating impotence
HU9301272D0 (en) Method for treating inflammations and wounds using plasminogene activator inhibitors
ZA949346B (en) Composition and process for treating metal
PL329893A1 (en) Method of and compositions for treating and preventing hyperuricaemia
GB9619153D0 (en) Device for and method of controlling electromagnetic loads
AU3401199A (en) Method and composition for treating psoriasis
GB2288816B (en) Double stabilized stainless-type steel and method of manufacture thereof
ZA932483B (en) Method and composition for treating acne
AU3838793A (en) Method for preventing and treating atherosclerosis
NO965497L (no) Fremgangsmåte for kontrollert fiksering av avleiringsinhibitor i en underjordisk formasjon
IL120128A0 (en) Compositions for the treatment of androgenetic alopecia and hirsutism
AU5819996A (en) Topically applicable agents for treating and preventing alopecia
GB9710628D0 (en) Method for topical treatment of androgenic alopecia
AU7471496A (en) Topical lotion and method for treatement of androgenic alopecia
EP0938296A4 (en) METHOD FOR TREATING ALOPECIA
PL306093A1 (en) Cataract treating agent and method of obtaining same
AU5957794A (en) Compositions and method for the inhibition of phagocytes

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20141010